Bactiguard Updates Trauma License Agreement with Zimmer Biomet
Reuters
Dec 19, 2025
Bactiguard Updates Trauma License Agreement with Zimmer Biomet
Bactiguard Holding AB has announced an update to its trauma license partnership agreement with Zimmer Biomet. The revised agreement focuses on the continued commercialization of the ZNN Bactiguard coated trauma nail system in European markets, selected Middle East and Africa (MEA) markets, and Japan. Under the new terms, Bactiguard will receive royalties on actual net sales and a quarterly fixed fee from Zimmer Biomet, with the annual fixed fees amounting to at least half of the minimum royalty from the previous agreement. The updated agreement is effective immediately and will not negatively impact Bactiguard's financial outlook for 2025 or its strategic and financial targets for 2030. Bactiguard also regains the remaining global rights within trauma as part of the update.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiguard Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20251219:BIT:8409:0) on December 19, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.